From Growth factor shows promise for Phelan-McDermid syndrome
"Last week, a separate set of researchers announced that the drug appears to be safe and effective in a trial of 53 adolescents and adults with Rett syndrome."
The inference is that IGF-1 was the drug being used instead of NNZ-2566. Only later on do you learn that:
"The Rett trial uses a modified form of IGF-1 that includes only the first three amino acids, but which may induce production of the full-length form in the brain"
I have noticed in a number of articles IGF-1 was being hyped and NNZ-2566 downplayed or not mentioned (as in the above announcement). To me IGF-1 is a competitor.
Wider autism efficacy potential for nnz-2566, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.42 |
Change
0.320(1.59%) |
Mkt cap ! $2.579B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $1.389M | 68.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 271 | $20.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.44 | 1102 | 6 |
View Market Depth
| Last trade - 13.28pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |